Literature DB >> 33460573

CDK4/6 inhibition in early-stage breast cancer: how far is it from becoming standard of care?

Binghe Xu1, Ying Fan2.   

Abstract

Entities:  

Year:  2021        PMID： 33460573     DOI： 10.1016/S1470-2045(20)30757-9

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  3 in total

Review 1.  Breast Cancer Stem-Like Cells in Drug Resistance: A Review of Mechanisms and Novel Therapeutic Strategies to Overcome Drug Resistance.

Authors:  Taniya Saha; Kiven Erique Lukong
Journal:  Front Oncol       Date:  2022-03-21       Impact factor: 6.244

2.  FKBP52 and FKBP51 differentially regulate the stability of estrogen receptor in breast cancer.

Authors:  Makoto Habara; Yuki Sato; Takahiro Goshima; Masashi Sakurai; Hiroyuki Imai; Hideyuki Shimizu; Yuta Katayama; Shunsuke Hanaki; Takahiro Masaki; Masahiro Morimoto; Sayaka Nishikawa; Tatsuya Toyama; Midori Shimada
Journal:  Proc Natl Acad Sci U S A       Date:  2022-04-08       Impact factor: 12.779

3.  Ribociclib Induces Broad Chemotherapy Resistance and EGFR Dependency in ESR1 Wildtype and Mutant Breast Cancer.

Authors:  Isabel Mayayo-Peralta; Beatrice Faggion; Liesbeth Hoekman; Ben Morris; Cor Lieftink; Isabella Goldsbrough; Lakjaya Buluwela; Joseph C Siefert; Harm Post; Maarten Altelaar; Roderick Beijersbergen; Simak Ali; Wilbert Zwart; Stefan Prekovic
Journal:  Cancers (Basel)       Date:  2021-12-16       Impact factor: 6.639
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.